Treg engineers take aim at autoimmunity
Elie Dolgin • November 9, 2021
Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.
Engineered adoptive T-cell therapies have already transformed the treatment of blood cancers. Now, several startups hope to harness the power of regulatory T cells (Tregs) to suppress immune responses and offer tolerance to transplant recipients, or to control the inflammation driving autoimmune disorders.
Continue reading at Nature Biotechnology.
A closer listen to lion calls may help map where the big cat is under threat.
Scientists remain split on whether rope-pulling ingenuity counts as tool use.